Journal of the American College of Cardiology
State-of-the-Art PaperTreatment Goals of Pulmonary Hypertension
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. McLaughlin has served on the speakers' bureau of Gilead and United Therapeutics (ended); has acted as a consultant or member of advisory board/steering committees of Actelion, Bayer, Gilead, and United Therapeutics; and has received institutional grant/research support from Actelion, Bayer, lkana, and Novartis. Dr. Gaine has served on advisory boards and received speaker/consulting fees from Actelion, GlaxoSmithKline, Pfizer, and United Therapeutics; and has received investigator feed for participation in pharmaceutical trials from Actelion, GlaxoSmithKline, Novartis and United Therapeutics. Dr. Howard has received honoraria for speaking from Actelion, GlaxoSmithKline, Pfizer, and Bayer; consultancy fees from Actelion, GlaxoSmithKline, Pfizer, Eli Lilly and Company, and Bayer; support for congress attendance from Actelion, GlaxoSmithKline, Eli Lilly and Company, and Bayer; and research grants from Actelion, Pfizer, and Bayer. Dr. Leuchte has received fees for lectures and consulting from Actelion, Bayer Vital, Bayer Healthcare, GlaxoSmithKline, Pfizer, United Therapeutics, Lilly, and Novartis. Dr. Mehta has received research grants from Actelion; investigator fees for participation in pharmaceutical clinical trials from Actelion, Bayer, Gilead, GlaxoSmithKline, Ikaria, Lilly, and United Therapeutics; and consulting and speaking fees from Actelion, Bayer, and GlaxoSmithKline. Dr. Palazzini has received speaker fees from Actelion, GlaxoSmithKline, Bayer, and United Therapeutics. Dr. Park has served as a consultant/adviser to Actelion Pharmaceuticals, Bayer, Gilead Sciences, and United Therapeutics. Dr. Tapson has received research grants/funding from Actelion, Bayer, Ikaria, Gilead, Novartis, and United Therapeutics; consulting fees from Actelion, Bayer, Gilead, Lung LLC, and United Therapeutics; and speaking honoraria from Actelion, Bayer, Gilead, and United Therapeutics. Dr. Sitbon has acted as a consultant for Actelion Pharmaceuticals Ltd., Bayer HealthCare, Eli Lilly and Company, GlaxoSmithKline, Pfizer, and United Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.